Sk Chemicals Co., Ltd.

Tiumbio Co., Ltd.

Ewha University-Industry Collaboration Foundation

Sunkyong Industries Co., Ltd.

In2gen Co., Ltd.

Hun-Taek Kim

Bong-Yong Lee

Dae-Kee Kim

In-Young Song

Ji-Hye Lee

Jae-Sun Kim

Yung-Jue Bang

Yun Jung Lim

Yong-Kook Kim

Ju Young Lee

Sang-hwan Kang

Myoung-Soon Park

Ho Soon Lee

Hyun Jung Lee

So-young Lee

Jae Won Choi

Mahn-Hoon Park

Keun-Ho Ryu

Jong-Wan Kim

Jaeseung Ahn

Yong-Hyuk Kim

Euisun Park

Il-Sang Cho

Ho-Soon Lee

Seo Yeon Son

Hyun-Jung Lee

Jinsoo Lim

Jung-Hoon Oh

Dong Chul Shin

Ho Chul Shin

Young-Woo Kim

Seon-Mi Kim

Sung-hoon Park

Jung A Lee

Jong-Il Ryu

Joon Hun Choi

Min-Sun Kim

Young Jae An

Je Ho Ryu

Jung Bum Yi

Yeo-Jin Park

Key Hyup Kim

Won-No Youn

Joon-Gyo Oh

Young-Ah Shin

Min-Young Han

Ganghyeok Kim

Taekyung Yoo

Jong-Seob Im

Yong-Youn Hwang

Dong-Chul Shin

Minhee Lee

Jongsik Gam

Young Ah Shin

Namkyu Lee

Seon-MI Kim

Hye-Min Kim

Mahn Hoon Park

Hoechul Jung

Hoe-chul Jung

Key-An Um

Hong-Kee Kim

Jin-Wook Jang

Seok-chan Kang

Min Sun Lee

Dongchul Shin

Sang-Hwan Kang

So-Young Lee

Sang-Wook Hwang

Jun-Sung Park

Gwan-Young Kim

Seok-Chan Kang

Salts and crystalline forms of (R)-4-((2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4′-piperidine]-3(2H,4H,7H)-yl)-1-phenylethyl)amino)butanoic acid (formula (1)) show excellent physicochemical properties including, for example, hygroscopicity, related substances, chemical stability. The salts and crystalline forms are useful and suitable for pharmaceutical uses such as the preparation of a pharmaceutical composition containing the same as an active ingredient.

Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof

A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.

Fusion protein having factor VII activity

The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-&#x3b2; (TGF-&#x3b2;) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

The present invention provides a pharmaceutical composition with improved stability, comprising a fusion protein comprising Factor VII (FVII) and transferrin, as an active ingredient, wherein the transferrin is linked to the C-terminus of the FVII; and trehalose or glycine as a bulking agent. The composition can store FVII and a variant thereof stably at room temperature for a long period of time. Thus it can be used as a useful therapeutic agent for patients suffering from hemophilia or congenital FVII deficiency.

Pharmaceutical composition with improved stability containing factor VII fusion protein

Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.

Process for producing and purifying factor VIII and its derivatives

Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure.

Percutaneous absorption preparation containing donepezil, and method for preparing same

Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.

Fusion protein having factor IX activity

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

A compound of the formula: Wherein A, A, X, Rand R3 are as defined herein, or a composition containing the same, which compound is useful in treating renal-, liver- or pulmonary fibrosis.

2-pyridyl substituted imidazoles of the formula (I) as shown in claim, are provided, which are useful in the treatment of diseases mediated by ALK5 or ALK4 inhibitors or both.

Compounds of the formula: wherein R1, R2, R3, A1 and A2 are as defined herein, which are used advantageously in inhibiting the TGF-&#x3b2; and/or activin signaling pathway in mammals.

The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.

Factor VIII polypeptide

Pyrimidine acyclonucleoside derivatives

Growing community of inventors

Seoul, South Korea

Hun-Taek Kim